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Abstract
The treatment of neurodegenerative diseases presents a growing need for
innovation in relation to recent evidence in the field of reconstructive therapy
using stem cells. Understanding the molecular mechanisms underlying
neurodegenerative disorders, and the advent of methods able to induce neuronal
stem cell differentiation allowed to develop innovative therapeutic approaches
offering the prospect of healthy and perfectly functional cell transplants, able to
replace the sick ones. Hence the importance of deepening the state of the art
regarding the clinical applications of advanced cell therapy products for the
regeneration of nerve tissue. Besides representing a promising area of tissue
transplant surgery and a great achievement in the field of neurodegenerative
disease, stem cell research presents certain critical issues that need to be carefully
examined from the ethical perspective. In fact, a subject so complex and not
entirely explored requires a detailed scientific and ethical evaluation aimed at
avoiding improper and ineffective use, rather than incorrect indications, technical
inadequacies, and incongruous expectations. In fact, the clinical usefulness of
stem cells will only be certain if able to provide the patient with safe, long-term
and substantially more effective strategies than any other treatment available.
The present paper provides an ethical assessment of tissue regeneration through
mesenchymal stem cells in neurodegenerative diseases with the aim to rule out
the fundamental issues related to research and clinical translation.
Key words: Mesenchymal stem cells; Neurodegenerative diseases; Stem cell research;
Stem cell therapy; Ethical principles; Patient safety
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Core tip: Neurodegenerative diseases constitute a set of pathologies affecting the central
nervous system whose main characteristic is a chronic and selective process of neuronal
cell death. The study of stem cells and the advent of new methods able to induce
neuronal differentiation, is having a significant impact in this sense in recent years,
offering the prospect of transplanting healthy and perfectly functional cells, able to
replace those diseased. The objective the present paper is to contribute to the
construction of an ethical framework that allows a close monitoring of the scientific
activity in the experimental and translational fields.
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INTRODUCTION
Modern transplant surgery presents an impressive need to explore the biological
reconstructive possibilities in different branches of medicine. Hence, it is important to
deepen the state of the art regarding the clinical applications and ethical implications
of cell therapies in neuronal regeneration.
Over the last  few years,  in the field of  tissue grafts  in patients  suffering from
neurodegenerative diseases,  a  broad perspective has been opened,  linked to the
possibility of growing in the laboratory differentiated cells and tissues from isolated
lines of multipotent cells grown on specific physiological substrates[1-4].
The destruction of the tissue architecture and the impairment of the function of an
organ related to the death of the cells of which it is constituted are at the basis of the
majority of the pathologies that afflict the population of the industrialized countries[5].
Regenerative medicine is a branch of medicine that aims to permanently recover
damaged tissues and organs through the exploitation of the regenerative potential of
stem cells[6-8].  Regenerative medicine, therefore, includes all  the therapies that,  in
pursuing the goal of regeneration, use the potential of stem cells, locally stimulated
both to duplicate and to differentiate, to be transferred after appropriate selection and
extraction[9].
Understanding the molecular mechanisms underlying neurodegenerative disorders
and the advent of methods able to induce neuronal stem cell differentiation have
allowed the development of innovative therapeutic approaches offering the prospect
of  healthy  and perfectly  functional  cell  transplants  that  are  able  to  replace  sick
ones[10-13].
Mesenchymal stem cells (MSCs) have interesting tissue regenerative potentialities
in adult organisms[14]. MSCs are available in many tissues and have the capacity to
regenerate them in part or entirely once increased in number and differentiated. The
use  of  adult  MSCs  is  currently  one  of  the  research  areas  of  greatest  interest  in
regenerative medicine[15].
In recent years, research has focused on the standardization of protocols for the
isolation and expansion of MSCs from various tissue sources, on the characterization
of their phenotypic and biological properties, and on the development of advanced
therapies  that  combine  MSCs with  synthetic  scaffolds  and signalling  molecules
(growth  factors  and  tissue  differentiation)  for  the  construction  of  hybrid
constructs[16-18]. In fact, achieving full knowledge of the processes of self-replication
and proliferation would allow researchers to obtain an infinite source of tissues for
the treatment of degenerative diseases or of important lesions of the central nervous
system (CNS).
The  optimization  of  the  therapeutic  efficacy  of  MSCs  in  the  treatment  of
neurodegenerative diseases requires researchers to overcome biological and technical
challenges. Particularly, it is necessary to address the critical issues related to the
dosage and routes of administration, the identification of patients able to respond to
cell  replacement therapy, the host's  immunological  response,  the mechanisms of
action of the grafts and the adverse effects.
The affirmation of the potential use of MSCs in regenerative medicine, currently
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supported by promising scientific results, will allow researchers to meet the high
expectations raised in the community only if hinged in a context of transparency and
plurality  of  research,  in  full  respect  of  different  cultural  and  technical
backgrounds[19,20]. The protection of plurality makes it possible to deal in depth with
the issues of  regenerative therapy to understand its  mechanisms and to develop
effective treatments[21]. The lack of the integration of the different perspectives would
imply their subtraction from the biological foundations of clinical practice and the
exaltation  of  an  empirical  medicine  incapable  of  producing  new  knowledge,
depriving the community of the necessary scientificity[22].
Thus, while representing a promising area of tissue transplant surgery and a great
achievement in the field of neurodegenerative disease, stem cell research presents
certain  critical  issues  that  need  to  be  carefully  examined  from  an  ethical
perspective[23,24].
First, the progress of research must be supported by consolidated and transparent
evidence despite the enthusiasm derived from the results of preclinical and clinical
trials[25]. In fact, the clinical utility of MSCs will be certain only in the presence of safe
therapeutic  strategies,  validated  in  the  long  term,  that  are  determined  to  be
substantially more effective than any other available treatment. It is also necessary
that  the ethical,  legal  and commercial  aspects  concerning stem cell  research and
related clinical trials continue to be discussed on the basis of concrete objectives and
through medically objective, scientifically honest and socially useful strategies[26].
In such a context, the use of appropriate methodologies in medical science is crucial
for the ability to connect biology and clinical medicine as well as to offer the tools to
distinguish good clinical practices from para-scientific illusions[27].
The present paper provides an ethical assessment of tissue regeneration through
MSCs in neurodegenerative diseases with the aim outlining the fundamental issues
related to research and clinical translation.
MSCs IN NEURODEGENERATIVE DISEASES
The  diseases  of  the  CNS  represent  a  heterogeneous  category  of  pathological
conditions with distinct etiopathogenetic and symptomatological characteristics, for
which a cure has not yet been identified[28]. Specifically, neurodegenerative diseases
constitute a set of pathologies affecting the CNS whose main characteristic is a chronic
and selective process of neuronal cell  death.  Neuronal deterioration is due to an
inevitable loss of brain function that occurs, depending on the type of disease, with
cognitive impairment, dementia, motor deficits, and behavioural disorders, more or
less  serious.  Despite  the  partial  overlaps  correlated  with  symptomatology  and
pathological  progression,  among  the  different  pathologies  studied  in  tissue
regeneration, it is possible to distinguish Parkinson's disease, Alzheimer's disease
(AD), Huntington's disease, multiple sclerosis, and amyotrophic lateral sclerosis[29].
The  treatment  of  neurodegenerative  diseases  presents  a  growing  need  for
innovation in relation to recent evidence in the field of reconstructive therapy using
stem cells[30,31].  Hence, it  is  important to deepen the state of the art regarding the
clinical applications of advanced cell therapy products for the regeneration of nerve
tissue.  At present,  there is  no cure for neurodegenerative diseases,  but there are
pharmacological treatments available to counteract some symptoms. The effort of the
scientific community is to understand the molecular mechanisms underlying these
diseases to intervene with new therapeutic approaches, including genetic approaches.
The study of  stem cells  and the advent of  new methods able to induce neuronal
differentiation have had a significant impact in this sense in recent years, offering the
prospect of transplanting healthy and perfectly functional cells that are able to replace
those that are diseased.
MSCs are present in the bone marrow, where they form the stromal counterpart of
the haematopoietic stem component, but they are also present in the peripheral blood,
in the umbilical cord and in other sites, including muscle tissue, adipose tissue, the
synovium, and the periosteum[32]. MSCs represent a topic of growing interest and a
valid  therapeutic  alternative  in  the  treatment  of  neurodegenerative  diseases.
Currently, MSCs have been studied in the field of several neurodegenerative diseases
and acute brain injuries, demonstrating interesting safety profiles in intravenous and
intrathecal administration.
Among the different applications under investigation, substantial progress has
been  recorded in  multiple  sclerosis,  where,  consistent  with  numerous  scientific
contributions, the administration of human umbilical cord blood-derived MSCs or
human bone marrow-derived MSCs has demonstrated an immunomodulatory effect
able  to  provide  clinical  stabilization,  an  improvement  of  the  symptoms  and  a
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reduction of the onset of relapse[33-37].
The  clinical  application  of  MSCs  in  the  treatment  of  Parkinson's  disease
presupposes, on the contrary, the overcoming of numerous challenges in relation to
the results obtained in animal models and clinical trials[38-41]. The results obtained so
far allow cautious optimism in relation to the demonstration of a neurodegenerative
effect and a slowing of disease progression in subjects treated with MSCs[42-44].
The therapeutic use of MSCs in AD must still be developed despite extremely high
expectations. At present, preclinical evidence supporting the mechanisms of action
and potential therapeutic implications is abundant[45]. Because of the reliability of the
preclinical results, MSC-based therapies have been approved for human trials. Early
evidence on the safety and tolerability of the intrathecal administration of allogeneic
human umbilical cord blood-derived MSCs, even in the absence of transplant-related
adverse events, did not demonstrate significant delays in cognitive decline during
follow-up.  Despite  these results,  several  other  trials  are  underway to clarify  the
therapeutic relevance of MSCs and their implications for the course of AD.
Concerning amyotrophic lateral sclerosis, the injection of autologous human bone
marrow-derived MSCs into the spinal cord has shown in different studies the ability
to induce an improvement of functional assessment scale scores, a better response to
treatment and a slowing of disease progression[46-48].
Further  clinical  studies  have  demonstrated  the  potential  efficacy  of  human
mesenchymal stem cell administration after ischaemic stroke. Specifically, it has been
documented that hBM-MSC transplantation is capable of improving clinical outcomes
and reducing mortality rates[49]. In addition, an improvement in performance in daily
activities and a decrease in cerebral atrophy in patients undergoing autologous hBM-
MSC transplantation were noted 6 weeks after the ischaemic event. In some trials
aimed at assessing the early effects of treatment, the administration of autologous
MSCs after stroke was able to determine a reduction in the size of the infarct area[50].
Again, recent studies have demonstrated that the administration of MSCs promotes
recovery in traumatic brain injury due to oxidative stress reduction[51-54].  Overall,
autologous mesenchymal cell transplantation has highlighted, together with high
safety profiles, the ability to support the repair of neurological damage, inducing an
improvement in functional performance[55,56].
Finally, as already mentioned, despite the proven potential of MSCs to trigger and
regulate  the process  of  neuronal  regeneration,  several  factors  limit  their  clinical
translation  in  neurology.  The  application  difficulties  due  to  the  lack  of  clinical
experience,  controversies  concerning  the  results  obtained  and  the  conflicting
conclusions on potential  benefits  or side effects can be overcome only through a
careful discussion of the ethical and regulatory issues related to the subject[57-59].
ETHICAL ISSUES RELATED TO STEM CELL RESEARCH AND
APPLICATIONS IN NEURODEGENERATIVE DISEASES
General principles
For other ethical issues associated with scientific research and clinical medicine, as in
the case of stem cell research and applications to transplant therapy, the fundamental
criterion of evaluation lies in the defence and promotion of the integral good of the
human person, according to its peculiar dignity[60].
In this regard, it  is worth remembering that every medical intervention on the
human person is  subject  to  limits  that  are  not  reduced to  the  possible  technical
impossibility of  realization but are linked to respect  for  the same human nature
understood in its integral meaning[61].
The most important evaluations regarding the fundamental principles must be
directed to the vulnerability of the individual. Neurodegenerative diseases, in fact,
determine  a  state  of  vulnerability  related  to  the  evolution  of  the  disease  or  to
situational  factors,  which  makes  patients  more  susceptible  to  exploitation.  The
condition of fragility experienced by the subjects of the experimentation imposes
particular care on the part of the investigators in the planning of clinical trials that
contemplate fully informed and voluntary participation[62-64]. The finding of conditions
such as impaired cognitive performance, mental and motor disability, and economic
and social  disadvantages  must  lead to  the introduction of  further  guarantees  to
protect patients' rights and wellbeing as well as safeguards to limit exposure to undue
influences[65].
Furthermore, it is necessary to highlight how the defence of research participants’
rights presuppose, together with the protection against avoidable damages, a careful
evaluation  of  the  benefits  for  the  person  and society.  Professionals  involved  in
research and clinical trials should prevent physical, psychological, economic and legal
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bias with a view to maximize patient advantages.
Risk assessment and safety in clinical research
Historically, some inconsistencies found in the preclinical phase have precluded the
clinical  translation  of  some  stem-cell-based  therapies[66,67].  In  this  context,  the
therapeutic application of MSCs in animal models provided safety tests that favoured
the  approval  of  human  clinical  trials.  Likewise,  human  experimentation  was
supported by the ease of the isolation and manipulation of MSCs and by evidence of
efficacy related to regenerative and immunomodulatory potentials[68].
Nevertheless,  several  scientific  contributions  on  the  subject  of  cell  therapies
emphasize the need to address - in advance of clinical research - the issues of long-
term safety, tolerability, and efficacy of the treatments under investigation[69]. The
cellular product used for research purposes must meet the quality standards required
by local legislation through the support of preclinical data that prove the safety of
cells, the procedure, and the effective ability of MSCs to differentiate into nerve cells
both in the laboratory and in the receiving host. Likewise, the use of mesenchymal
stem-cell-based products must be corroborated by precise data on the dose of toxicity,
reproductive toxicity, and carcinogenesis.
To date, the main problems are unwanted differentiation, the potential suppression
of the anti-tumour response and the neo-angiogenetic capacity of the transplanted
MSCs[70].  In fact,  MSCs have shown paracrine activity with the release of growth
factors and cytokines able to stimulate angiogenesis, slow down the processes of cell
death and block inflammatory processes. For these reasons, safety studies must be
extended to the classification and resolution of possible local complications as well as
to systemic adverse effects through the provision of long follow-up periods[71]. In fact,
clinical practice is the best test for evaluating the adverse effects and limitations of cell
therapy regarding the functionality of grafting after transplantation. Based on these
assumptions,  the  safety  issues  still  under  debate  must  be  carefully  discussed
regardless of the promising results obtained from therapies with MSCs.
Clinical trials
MSCs have been or are currently being studied in approximately 46 phase I and II
clinical trials (www.clinicaltrials.gov). However, not all trials fully meet regulatory
criteria,  preclinical  studies are often weak and insufficient,  cellular products are
difficult to reproduce in a standardized manner, and results are sometimes supported
by poor evidence.
In this regard, it should be noted that, as with any type of pioneering research, no
one can provide guarantees of success before the availability of evidence. Hence, it is a
duty to pursue every area of research on the sole condition that these are rational,
verifiable and methodologically appropriate studies[72].
Therefore, the clinical testing of MSCs requires the definition of unified regulations
regarding the procedures for the preparation and maintenance of cellular products
with standardized methods and techniques shared between laboratories. Equally
evident is the difficulty in obtaining standard reference procedures precisely because
of the heterogeneity of both the patients and the original tissue samples, as well as of
the expanded cultures.
As  outlined  in  the  previous  section,  the  clinical  results  highlight  the  overall
potential  efficacy  of  MSCs  in  the  treatment  of  neurodegenerative  diseases.
Nevertheless, it is desirable that the therapeutic profile of MSCs in the neurological
field be further investigated in larger cohorts. This perspective involves meticulous
scientific  planning aimed at  overcoming the  obstacles  derived from the  need to
respect the heterogeneity of patients and to refine the inclusion and exclusion criteria.
Moreover, the efficacy of the tested treatments must be proven through different
clinical  evaluation systems,  objective and subjective,  included in long follow-up
periods  in  which  the  integration  of  diagnostic  imaging,  laboratory  monitoring,
functional evaluation and quality of life questionnaires are contemplated.
Finally, the obligation for experimenters in clinical trials to ethically evaluate the
commitment  of  economic  and  human  resources  related  to  the  organization  of
facilities,  the clinical  management of  patients  and the traceability  of  procedures
should be noted. Similarly, the analysis of sustainability must include the increased
use of resources related to the recruitment of a large cohort, the high turnover of
coordinators and dedicated professionals, the possible extension of the study period
and follow-up, and the need for the disclosure of results. Obviously, all evaluations
on the sustainability and use of resources presuppose, in addition to the intervention
of  the  professionals  involved,  a  huge  effort  on  the  part  of  governments  and
supranational organizations that finance research and have enormous possibilities for
coordination in the allocation of funds and in management of the objectives of the
international scientific community.
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Justice in research and treatment
The considerations related to justice and equity are issues of remarkable importance,
although they are often neglected in the context of scientific research and clinical
practice.  In  the  field  of  new biotechnologies  and,  in  particular,  stem-cell-based
treatments, the economic costs of products and interventions can be extremely high,
as can the time and resources necessary for development and therapeutic  use[73].
Therefore, it is crucial to focus on the costs and availability of treatments to increase
sustainability and reduce inequity in access to care[74,75].
Issues  related  to  justice  in  the  context  of  MSC  research  and  therapy  can  be
schematically linked to production, biobanking and clinical translation.
Regarding the processing of stem cells and the manufacture of cellular products,
there  is  widespread  evidence  of  a  greater  effort  to  standardize  and  rationalize
production in the field of regenerative medicine compared to other branches[76]. The
development  of  platform  technologies  and  large-scale  production  represent  an
important perspective that can reduce time, labour and costs with interesting ethical
implications  for  access  to  treatment.  However,  this  strategy  is  currently  poorly
practicable in the field of MSCs and “autologous” cell interventions that are certainly
more expensive and less readily feasible due to production times. Therefore, in light
of the foregoing and with a view to planning future strategies,  a careful balance
between the needs for cost reduction and accessibility and the implications in terms of
safety and effectiveness is essential.
Similar  considerations can be formulated regarding the policy and practice of
biobanking. Although still  at a preliminary stage in technological and regulatory
development,  stem cell  collection,  storage  and  use  systems  are  an  indisputable
resource  for  regenerative  medicine[77].  Ideally,  the  development  of  large-scale
biobanking systems could lead to an amplification of stem cell assets and a reduction
in  costs  of  absolute  utility  in  the  implementation  of  tissue  engineering  pro-
grammes[78-80].  The  structuring  of  sustainable  systems  includes  the  guarantee  of
accessibility, the regulation of use in the experimental and therapeutic fields, the
refinement  of  consent  in  its  different  forms  and  the  protection  of  information
processes[81].  Therefore, large-scale biobanking requires a critical characterization
based on a careful assessment of potential benefits as well as practical and ethical
challenges.
Finally, it must be stated that all the efforts made in the experimental and clinical
field must be supported by scientific transparency and data sharing. In fact, despite
the pressures deriving from commercial competition, it is fundamental to protect
patients’ hopes and to avoid the feeding of false expectations or, worse, fraudulent
therapies[82-84]. For these reasons, in consideration of the social and not merely scientific
scope  of  the  objectives  pursued,  it  is  necessary  that  the  professionals  involved
consider the ethical implications related to justice as closely related to research and
clinical practice.
POSITION STATEMENT
Stem cell  research and treatment require considerations about different issues of
medical,  scientific,  moral  and  ethical  relevance.  The  field  of  MSCs  facilitates
discussion among stakeholders because it is free from the problems inherent to the
use  of  human embryonic  stem cells.  However,  several  issues  need an open and
constructive debate able to support the rapid development of knowledge and the
promising application of MSCs in regenerative medicine.
To prevent  the onset  of  prejudices  that  can nullify  the efforts  of  the  scientific
community in such a sensitive area of medical science development, it is necessary to
formulate recommendations for good experimental and clinical practice[85].
First,  it  is  desirable to carry out continuous and responsible research aimed at
generating  evidence  on  the  therapeutic  mechanisms  of  MSCs  with  regard  to
differentiation capacity and paracrine activity. The expansion of knowledge must also
clarify the persistent doubts about the long-term behaviour and adverse effects of
MSCs.
Second, with regard to the future objectives of the research, further studies are
suggested on the epigenetics of MSCs, immunogenicity, host immune response, and
the stability of the grafts.
Progress in research and therapy requires the codification of universal criteria and
standards  for  the  processing of  MSCs.  For  example,  the  availability  of  a  shared
methodology for in vitro differentiation could eliminate the limitations resulting from
the current poor understanding of the MSC profile.
Moreover, precisely for safety concerns related to the clinical use of MSCs, the
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efforts of the scientific community must be aimed at the manufacture of traceable,
tolerable and effective cellular products. The translation into clinical practice and the
marketing of cellular products presupposes the validation of standardized operating
procedures as well as a careful review of the aspects related to functionality, safety
and banking.
Ultimately, a significant political and legislative commitment at the international
level is needed regarding the approval of public funding able to implement research
activities and support clinical translation. The fair distribution of funding and the
availability of equal opportunities for researchers determine a liberalization able to
accelerate the development of the regenerative approach through MSCs. Only the
guarantee of equity in all phases of scientific research will make it possible to respect
the principles of justice to protect patients[85].
CONCLUSION
In the heterogeneous and complicated scenario currently characterizing the treatment
of neurodegenerative diseases – in terms of the functional needs of patients and
research,  innovation,  resources,  and  medico-legal  issues  –  a  rigorous  ethical
framework and a strict  surveillance of scientific activity in the experimental and
translational  fields  are  imperative.  It  is  also  necessary  that  ethical,  legal  and
commercial aspects concerning stem cell research and related clinical trials continue to
be  discussed  on  concrete  objectives  and  through  strategies  that  always  present
themselves as medically objective, scientifically honest and socially useful.
Cell therapies and regenerative medicine, increasingly based on the progress of
stem cell biology, have begun to lay the foundations of future clinical practice.
The progress of medical therapy based on MSCs generates multiple expectations
but requires a rigorous methodological approach. In particular, a subject so complex
and not entirely explored requires a detailed scientific and ethical evaluation aimed at
the  avoidance  of  improper  and ineffective  use  rather  than incorrect  indications,
technical inadequacies, and incongruous expectations.
Despite the enthusiasm of stem cell studies, nothing could be more wrong than the
transplantation of stem cells in humans without consistent results and consolidated
evidence. In fact, the clinical usefulness of stem cell transplantation strategies will be
certain  only  if  they  are  able  to  provide  the  patient  with  safe,  long-term  and
substantially more effective treatments than any other strategy available.
Conclusively, the many challenges still open in the exaltation of the potential of
MSCs in the neurological  field require an integrated multidisciplinary approach
aimed  at  the  contextualization  of  scientific  advances  and  responsible  clinical
translation of therapeutic findings. Therefore, the growing focus on the therapeutic
implications of MSCs should prompt scientists, physicians, regulatory bodies and
bioethicists to act in a coordinated manner to promote appropriate and evidence-
based clinical applications.
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